Biogen, UCB Take A Leap In Lupus With Promising Phase 3 Results

UCB SA (OTC:UCBJY) (OTC:UCBJF) (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ:BIIB) on Thursday presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP).

The companies released topline results in September 2024.

UCB and Biogen unveiled detailed results from their Phase 3 PHOENYCS GO trial this week at EULAR 2025, showing that their investigational lupus drug dapirolizumab pegol (DZP) significantly improved disease activity and fatigue in patients with systemic lupus erythematosus (SLE).

The data bolster Biogen's presence in immunology as the company also sharpens its focus on neuroscience, announcing a $46 million collaboration with City Therapeutics to develop RNAi therapies targeting central nervous system disorders.

Together, the trial results and new partnership underscore Biogen's dual strategy: strengthening late-stage autoimmune assets while replenishing its early pipeline with next-gen CNS innovations.

Also Read: Biogen Beats Q1 Earnings Expectations As Two Newcomer Drug Sales Spike, Avoids Tariff Impact

These results were presented at EULAR 2025, the ...